Senti Biosciences (SNTI) Competitors $3.97 -0.01 (-0.25%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNTI vs. RANI, ANIX, ADAG, ASRT, ME, PWUP, CTMX, KPTI, ANL, and RVPHShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Rani Therapeutics (RANI), Anixa Biosciences (ANIX), Adagene (ADAG), Assertio (ASRT), 23andMe (ME), PowerUp Acquisition (PWUP), CytomX Therapeutics (CTMX), Karyopharm Therapeutics (KPTI), Adlai Nortye (ANL), and Reviva Pharmaceuticals (RVPH). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Rani Therapeutics Anixa Biosciences Adagene Assertio 23andMe PowerUp Acquisition CytomX Therapeutics Karyopharm Therapeutics Adlai Nortye Reviva Pharmaceuticals Rani Therapeutics (NASDAQ:RANI) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, community ranking, institutional ownership and media sentiment. Which has preferable valuation and earnings, RANI or SNTI? Rani Therapeutics has higher revenue and earnings than Senti Biosciences. Rani Therapeutics is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani Therapeutics$2.72M29.49-$33.97M-$1.06-1.32Senti Biosciences$2.56M7.12-$71.06M-$15.56-0.26 Does the MarketBeat Community prefer RANI or SNTI? Rani Therapeutics received 27 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 81.58% of users gave Rani Therapeutics an outperform vote while only 40.00% of users gave Senti Biosciences an outperform vote. CompanyUnderperformOutperformRani TherapeuticsOutperform Votes3181.58% Underperform Votes718.42%Senti BiosciencesOutperform Votes440.00% Underperform Votes660.00% Do insiders & institutionals have more ownership in RANI or SNTI? 30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are held by institutional investors. 53.3% of Rani Therapeutics shares are held by company insiders. Comparatively, 15.9% of Senti Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend RANI or SNTI? Rani Therapeutics presently has a consensus target price of $11.71, suggesting a potential upside of 736.73%. Senti Biosciences has a consensus target price of $10.00, suggesting a potential upside of 151.89%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, RANI or SNTI? Rani Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.69, suggesting that its stock price is 169% more volatile than the S&P 500. Does the media refer more to RANI or SNTI? In the previous week, Rani Therapeutics had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 4 mentions for Rani Therapeutics and 3 mentions for Senti Biosciences. Rani Therapeutics' average media sentiment score of 1.43 beat Senti Biosciences' score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rani Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RANI or SNTI more profitable? Senti Biosciences' return on equity of -154.84% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -219.64% -56.71% Senti Biosciences N/A -154.84%-77.42% SummaryRani Therapeutics beats Senti Biosciences on 15 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.22M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.2645.9489.7417.16Price / Sales7.12415.011,117.09117.04Price / CashN/A182.1043.1037.86Price / Book0.263.894.784.78Net Income-$71.06M-$42.21M$120.31M$225.60M7 Day Performance-28.73%-2.15%-1.92%-1.23%1 Month Performance82.95%1.73%13.65%0.46%1 Year Performance-23.65%16.36%28.34%15.24% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.3392 of 5 stars$3.97-0.3%$10.00+151.9%-9.6%$18.22M$2.56M-0.264News CoverageGap UpRANIRani Therapeutics3.4519 of 5 stars$1.64-1.2%$11.71+614.6%-55.4%$93.92M$2.72M-1.57110ANIXAnixa Biosciences2.949 of 5 stars$2.85flat$8.50+198.2%-29.0%$91.71M$210,000.00-7.315ADAGAdagene1.9972 of 5 stars$2.07+0.5%$5.00+141.5%+18.5%$91.64M$815,746.000.00260ASRTAssertio3.3686 of 5 stars$0.96+4.1%$3.25+239.2%-18.7%$91.47M$125.76M-1.2620Gap DownME23andMe2.3629 of 5 stars$3.42+2.1%$9.40+174.9%-80.8%$89.33M$219.64M-0.13770Positive NewsPWUPPowerUp AcquisitionN/A$11.43flatN/A+1.6%$88.81MN/A0.00N/ACTMXCytomX Therapeutics4.321 of 5 stars$1.13+1.8%$5.77+410.8%-22.7%$88.43M$101.21M6.53170News CoveragePositive NewsKPTIKaryopharm Therapeutics3.8015 of 5 stars$0.69-0.7%$5.00+619.5%-16.5%$87.69M$148.44M-0.61380ANLAdlai Nortye1.583 of 5 stars$2.36+3.1%$9.00+281.4%-75.5%$87.08M$5M0.00127Positive NewsGap UpRVPHReviva Pharmaceuticals3.012 of 5 stars$2.59-0.8%$15.50+498.5%-65.2%$86.61MN/A-2.355High Trading Volume Related Companies and Tools Related Companies Rani Therapeutics Alternatives Anixa Biosciences Alternatives Adagene Alternatives Assertio Alternatives 23andMe Alternatives PowerUp Acquisition Alternatives CytomX Therapeutics Alternatives Karyopharm Therapeutics Alternatives Adlai Nortye Alternatives Reviva Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNTI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
